A phase 1 study of Flavivirus vaccine (EMX-001).

Trial Profile

A phase 1 study of Flavivirus vaccine (EMX-001).

Planning
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs EMX-001 (Primary)
  • Indications Dengue; Yellow fever; Zika virus infection
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Apr 2018 New trial record
    • 26 Mar 2018 According to an Emergex Vaccines media release, company is planning to initiate this study in early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top